Symyx has acquired Integrity Biosolution in an all-cash transaction.
Integrity Biosolution provides contract formulation research and analytical services, providing solutions for large molecule biopharmaceuticals along with Good Manufacturing Practices (GMP) fill/finish services for Phase I and II clinical trial volumes. Specific terms of the acquisition were not disclosed.
The acquisition expands Symyx's Research Service offerings in life sciences into biologic formulations, complementing its existing chemical formulations services. The combination of Symyx and IntegrityBio creates a differentiated set of large molecule formulation services to customers in the pharmaceutical and biotechnology industries by combining IntegrityBio's formulation expertise with Symyx's advanced high-throughput research and informatics capabilities.
